Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study.

Publication ,  Journal Article
Patel, RS; Sreeram, V; Vadukapuram, R; Baweja, R
Published in: Schizophrenia research
October 2020

This study aims to find the prevalence of medication non-compliance among schizophrenia inpatients and to compare the relative risks of medication non-compliance with cannabis use disorders (CUDs) versus without CUDs. In addition, this study also examines the odds of medication non-compliance in schizophrenia inpatients with CUDs.This is a retrospective cross-sectional analysis of the nationwide inpatient sample. This sample includes 1,030,949 inpatients (age 18 to 65 years) from 2010 to 2014 with primary ICD-9 diagnoses of schizophrenia and other psychotic disorders, that were further sub grouped based on medication non-compliance. CUDs were recognized using the ICD-9 codes.The prevalence of medication non-compliance was 26% among schizophrenia inpatients. Multivariable analysis revealed that CUD comorbidity was a significant risk factor for medication non-compliance among schizophrenia patients when unadjusted (OR 1.49, 95%CI 1.469-1.503), and association remained significant even after adjusting for covariates (adjusted OR 1.38, 95%CI 1.268-1.489). Comorbid CUD was seen in young adults (18-35 years, 62.4%), males (80.5%), African Americans (54.1%) and low-income families below 25th percentile (48.6%) with personality disorders (10.5%).Medication compliance is a challenge among schizophrenia patients, which has a significant adverse impact on the course of illness. CUD Comorbidity increases the risk of medication non-compliance significantly among schizophrenia patients. In addition to case management, an integrated treatment model to address both substance use disorders and psychosis will translate into better long-term outcomes in schizophrenia patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Schizophrenia research

DOI

EISSN

1573-2509

ISSN

0920-9964

Publication Date

October 2020

Volume

224

Start / End Page

40 / 44

Related Subject Headings

  • Young Adult
  • United States
  • Schizophrenia
  • Retrospective Studies
  • Psychiatry
  • Middle Aged
  • Medication Adherence
  • Marijuana Abuse
  • Male
  • Inpatients
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, R. S., Sreeram, V., Vadukapuram, R., & Baweja, R. (2020). Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study. Schizophrenia Research, 224, 40–44. https://doi.org/10.1016/j.schres.2020.11.002
Patel, Rikinkumar S., Venkatesh Sreeram, Ramu Vadukapuram, and Raman Baweja. “Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study.Schizophrenia Research 224 (October 2020): 40–44. https://doi.org/10.1016/j.schres.2020.11.002.
Patel, Rikinkumar S., et al. “Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study.Schizophrenia Research, vol. 224, Oct. 2020, pp. 40–44. Epmc, doi:10.1016/j.schres.2020.11.002.
Patel RS, Sreeram V, Vadukapuram R, Baweja R. Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study. Schizophrenia research. 2020 Oct;224:40–44.
Journal cover image

Published In

Schizophrenia research

DOI

EISSN

1573-2509

ISSN

0920-9964

Publication Date

October 2020

Volume

224

Start / End Page

40 / 44

Related Subject Headings

  • Young Adult
  • United States
  • Schizophrenia
  • Retrospective Studies
  • Psychiatry
  • Middle Aged
  • Medication Adherence
  • Marijuana Abuse
  • Male
  • Inpatients